BOTHELL, Wash. (AP) ¿ Development-stage biotechnology company Seattle Genetics Inc. said Thursday its third-quarter loss narrowed on higher revenue from partnerships. The company lost $19.8 million, or 21 cents per share, compared with a loss of $21.8 million, or 27 cents per share, during the same period a year prior. Revenue rose 44 percent to $11.6 million from $8.1 million. Analysts polled by Thomson Reuters expected a loss of 25 cents per share on revenue of $9.4 million. The company's key partnership is with Genentech Inc., now part of Roche. The companies are developing potential cancer treatments. Shares of Seattle Genetics rose 12 cents to close at $9.85.
HOST // Robert Powell
Retirement Planning Event
More from Technology
The Trade Desk Remains a Pretty Unique Story - Tech Check
The online ad firm has seen strong growth in a U.S. market where Google, Facebook and Amazon loom large. And it's now entering China.
Why Wall Street Hasn't Lost Faith in Apple's New Toys
Hint: analysts have tons of faith. Watch the video.
Jim Cramer Thinks That Apple's New Products are 'No-Brainers'
Jim Cramer explains why he is more than ready to jump on the Apple bandwagon following Tuesday's event.